Manu Anantpadma

Manu Anantpadma

Auto-generated profile, based on publicly available information

Manu Anantpadma

Integrated Research Facility at Fort Detrick, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
YMYinghong Ma
Yinghong Ma
MAManu Anantpadma
Manu Anantpadma
JTJennifer M. Timpe
Jennifer M. Timpe
SSSaravanabalaji Shanmugam
Saravanabalaji Shanmugam
SSSher M. Singh
Sher M. Singh
MYMinKyung Yi
MinKyung Yi
Many aspects of the assembly of hepatitis C virus (HCV) remain incompletely understood. To characterize the role of NS2 in the production of infectious virus, we determined NS2 interaction partners among other HCV proteins during productive infection. Pulldown assays showed that NS2 forms complexes with both structural and nonstructural proteins, including E1, E2, p7, NS3, and NS5A. Confocal microscopy also demonstrated that NS2 colocalizes with E1, E2, and NS5A in dot-like structures near lipid droplets. However, NS5A did not coprecipitate with E2 and interacted only weakly with NS3 in pulldown assays. Also, there was no demonstrable interaction between p7 and E2 or NS3 in such assays. Therefore, NS2 is uniquely capable of interacting with both structural and nonstructural proteins. Among mutations in p7, NS2, and NS3 that prevent production of infectious virus, only p7 mutations significantly reduced NS2-mediated protein interactions. These p7 mutations altered the intracellular distribution of NS2 and E2 and appeared to modulate the membrane topology of the C-terminal domain of NS2. These results suggest that NS2 acts to coordinate virus assembly by mediating interactions between envelope proteins and NS3 and NS5A within replication complexes adjacent to lipid droplets, where virus particle assembly is thought to occur. p7 may play an accessory role by regulating NS2 membrane topology, which is important for NS2-mediated protein interactions and therefore NS2 function.

1 April 2015 in Cell Reports
Verified
Journal Article
Open access
DLDaisy W. Leung
Daisy W. Leung
DBDominika Borek
Dominika Borek
PLPriya Luthra
Priya Luthra
JBJennifer M. Binning
Jennifer M. Binning
MAManu Anantpadma
Manu Anantpadma
GAGaya Amarasinghe
Gaya Amarasinghe
During viral RNA synthesis, Ebola virus (EBOV) nucleoprotein (NP) alternates between an RNA-template-bound form and a template-free form to provide the viral polymerase access to the RNA template. In addition, newly synthesized NP must be prevented from indiscriminately binding to noncognate RNAs. Here, we investigate the molecular bases for these critical processes. We identify an intrinsically disordered peptide derived from EBOV VP35 (NPBP, residues 20-48) that binds NP with high affinity and specificity, inhibits NP oligomerization, and releases RNA from NP-RNA complexes in vitro. The structure of the NPBP/ΔNPNTD complex, solved to 3.7 Å resolution, reveals how NPBP peptide occludes a large surface area that is important for NP-NP and NP-RNA interactions and for viral RNA synthesis. Together, our results identify a highly conserved viral interface that is important for EBOV replication and can be targeted for therapeutic development.

12 November 2015 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
BRBethany A Rhein
Bethany A Rhein
LPLinda S Powers
Linda S Powers
KRKai Rogers
Kai Rogers
MAManu Anantpadma
Manu Anantpadma
BSBrajesh Kumar Singh
Brajesh Kumar Singh
WMWendy Maury
Wendy Maury
Ebola virus outbreaks, such as the 2014 Makona epidemic in West Africa, are episodic and deadly. Filovirus antivirals are currently not clinically available. Our findings suggest interferon gamma, an FDA-approved drug, may serve as a novel and effective prophylactic or treatment option. Using mouse-adapted Ebola virus, we found that murine interferon gamma administered 24 hours before or after infection robustly protects lethally-challenged mice and reduces morbidity and serum viral titers. Furthermore, we demonstrated that interferon gamma profoundly inhibits Ebola virus infection of macrophages, an early cellular target of infection. As early as six hours following in vitro infection, Ebola virus RNA levels in interferon gamma-treated macrophages were lower than in infected, untreated cells. Addition of the protein synthesis inhibitor, cycloheximide, to interferon gamma-treated macrophages did not further reduce viral RNA levels, suggesting that interferon gamma blocks life cycle events that require protein synthesis such as virus replication. Microarray studies with interferon gamma-treated human macrophages identified more than 160 interferon-stimulated genes. Ectopic expression of a select group of these genes inhibited Ebola virus infection. These studies provide new potential avenues for antiviral targeting as these genes that have not previously appreciated to inhibit negative strand RNA viruses and specifically Ebola virus infection. As treatment of interferon gamma robustly protects mice from lethal Ebola virus infection, we propose that interferon gamma should be further evaluated for its efficacy as a prophylactic and/or therapeutic strategy against filoviruses. Use of this FDA-approved drug could rapidly be deployed during future outbreaks. Filovirus outbreaks occur sporadically, but with increasing frequency. With no current approved filovirus therapeutics, the 2014 Makona Ebola virus epidemic in Guinea, Sierra Leone and Liberia emphasizes the need for effective treatments against this highly pathogenic family of viruses. The use of this FDA-approved drug to inhibit Ebola virus infection would allow rapid implementation of a novel antiviral therapy for future crises. Interferon gamma elicits an antiviral state in antigen-presenting cells and stimulates cellular immune responses. We demonstrate that interferon gamma profoundly inhibits Ebola virus infection of macrophages, which are early cellular targets of Ebola virus. We also identify novel interferon gamma-stimulated genes in human macrophage populations that have not been previously appreciated to inhibit filoviruses or other negative strand RNA viruses. Finally and most importantly, we show that interferon gamma given 24 hours prior to or after virus infection protects mice from lethal Ebola virus challenge, suggesting that this drug may serve as an effective prophylactic and/or therapeutic strategy against this deadly virus.

1 October 2018 in Antiviral Research
Verified
Journal Article
Closed access
PLPriya Luthra
Priya Luthra
JNJacinth Naidoo
Jacinth Naidoo
CPColette A. Pietzsch
Colette A. Pietzsch
SDSampriti De
Sampriti De
SKSudip Khadka
Sudip Khadka
CBChristopher F Basler
Christopher F Basler

1 May 2014 in Journal of Molecular Biology
Verified
Journal Article
Closed access
CBCraig S. Brown
Craig S. Brown
MLMichael S. Lee
Michael S. Lee
DLDaisy W. Leung
Daisy W. Leung
TWTianjiao Wang
Tianjiao Wang
WXWei Xu
Wei Xu
GAGaya Amarasinghe
Gaya Amarasinghe

1 June 2009 in Journal of General Virology
Verified
Journal Article
Closed access
SVSurender Vashist
Surender Vashist
MAManu Anantpadma
Manu Anantpadma
HSHimani Sharma
Himani Sharma
SVSudhanshu Vrati
Sudhanshu Vrati
Japanese encephalitis virus (JEV) genome is a single-stranded, positive-sense RNA with non-coding regions (NCRs) of 95 and 585 bases at its 5′ and 3′ ends, respectively. These may bind to viral or host proteins important for viral replication. It has been shown previously that three proteins of 32, 35 and 50 kDa bind the 3′ stem–loop (SL) structure of the JEV 3′ NCR, and one of these was identified as 36 kDa Mov34 protein. Using electrophoretic mobility-shift and UV cross-linking assays, as well as a yeast three-hybrid system, it was shown here that La protein binds to the 3′ SL of JEV. The binding was stable under high-salt conditions (300 mM KCl) and the affinity of the RNA–protein interaction was high; the dissociation constant (Kd) for binding of La protein to the 3′ SL was 12 nM, indicating that this RNA–protein interaction is physiologically plausible. Only the N-terminal half of La protein containing RNA recognition motifs 1 and 2 interacted with JEV RNA. An RNA toe-printing assay followed by deletion mutagenesis showed that La protein bound to predicted loop structures in the 3′ SL RNA. Furthermore, it was shown that small interfering RNA-mediated downregulation of La protein resulted in repression of JEV replication in cultured cells.